Navigation Links
Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/6/2008

- Presentation to be Webcast -

MONTVALE, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 10th Annual BIO CEO & Investor Conference on Monday, February 11, 2008 at 3:30 p.m. Eastern Time. The event will be held from February 11 - 13, 2008 at the Waldorf-Astoria Hotel in New York City.

Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2 initiatives for ALT-2074 in cardiovascular diseases and psoriasis, and alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones.

The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.

Note to Attendees: Synvista will be available for one-on-one meetings. Please arrange through BIO or by calling Kim Sutton Golodetz at Lippert/Heilshorn & Associates at 212-838-3777.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
5. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
6. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
7. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
8. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
9. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
10. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... The Arnold and ... Thomson Professor of Electrical Engineering and Computer Science at the Massachusetts Institute of ... the award recognizes an individual who has made and is continuing to make ...
(Date:7/20/2017)... BC, Canada (PRWEB) , ... July 20, 2017 , ... ... today announced the winning recipients of the 2017 IAC Awards at the 22nd World ... awards, the committee also named four faculty to receive the Distinguished Fellowship Awards. , ...
(Date:7/20/2017)... ... ... VIC Technology Venture Development™ (VIC™), is pleased to announce that James ... to strengthen and diversify VIC’s board. , "We are excited to have Jamie join ... business executive with a broad range of experience directly relevant to VIC as we ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):